USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA.
J Hematol Oncol. 2018 Jun 11;11(1):80. doi: 10.1186/s13045-018-0620-6.
Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.
内分泌治疗历来是治疗转移性激素受体阳性乳腺癌的基础。内分泌耐药的发展导致了新的内分泌药物联合治疗的发展。CDK4/6 抑制剂的使用显著改善了这组患者的无进展生存期。有多项关于使用 PI3K 抑制剂和 mTOR 抑制剂作为后续治疗线的研究，特别是用于内分泌耐药。治疗的最佳顺序应基于合并症、辅助治疗、生活质量、副作用谱和无病间期。
